Sanofi (SNYNF) Enterprise Value (2009 - 2025)
Sanofi (SNYNF) posted Enterprise Value of -$6.9 billion for Q1 2026, up 16.91% sequentially from -$8.3 billion in Q4 2025, and up 11.44% YoY from -$6.2 billion in Q1 2025.
Sanofi (SNYNF) Enterprise Value (2009 - 2025) Analysis & Trends
Sanofi (SNYNF) has 18 years of Enterprise Value data on file, last reported at -$6.9 billion in Q1 2026.
- Quarterly Enterprise Value rose 11.44% year-over-year to -$6.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$6.9 billion (up 11.44% YoY) and the FY2025 annual result came in at -$8.3 billion, down 10.1% from the prior year.
- Enterprise Value climbed to -$6.9 billion in Q1 2026 per SNYNF's latest filing, from -$8.3 billion in the prior quarter.
- The five-year high for Enterprise Value was -$6.9 billion in Q1 2026, with the low at -$17.1 billion in Q2 2025.
- Average Enterprise Value over 5 years is -$9.3 billion, with a median of -$8.4 billion recorded in 2023.
- Year-over-year, Enterprise Value surged 39.55% in 2022 and plunged 144.45% in 2025.
- Sanofi's Enterprise Value stood at -$12.6 billion in 2022, then grew by 28.4% to -$9.0 billion in 2023, then grew by 16.13% to -$7.6 billion in 2024, then slipped by 10.1% to -$8.3 billion in 2025, then climbed by 16.91% to -$6.9 billion in 2026.
- Business Quant data shows SNYNF's Enterprise Value at -$6.9 billion in Q1 2026, -$8.3 billion in Q4 2025, and -$10.4 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | -5.28 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | -22.05 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -9.35 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -7.89 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | -5.65 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | -12.04 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | -7.73 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | -12.77 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | 315.00 Mn |
| 10 | Sanofi | - | - | 9.49 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -8.34 Bn |
| Jun 30, 2025 | -17.08 Bn |
| Dec 31, 2024 | -7.58 Bn |
| Jun 30, 2024 | -6.99 Bn |
| Dec 31, 2023 | -9.03 Bn |
| Jun 30, 2023 | -8.36 Bn |
| Dec 31, 2022 | -12.62 Bn |
| Jun 30, 2022 | -6.98 Bn |
| Dec 31, 2021 | -11.16 Bn |
| Jun 30, 2021 | -11.55 Bn |
| Dec 31, 2020 | -16.60 Bn |
| Jun 30, 2020 | -17.39 Bn |
| Dec 31, 2019 | -10.39 Bn |
| Jun 30, 2019 | -7.39 Bn |
| Dec 31, 2018 | -7.95 Bn |
| Jun 30, 2018 | -7,160.67 Bn |
| Mar 31, 2018 | 202.71 Mn |
| Dec 31, 2017 | -12.04 Bn |
| Jun 30, 2017 | -11.78 Bn |
| Dec 31, 2016 | -10.94 Bn |